Prolonged Reponses Following ASCT and Standard Consolidation/Induction With Daratumumab Maintenance
June 20th 2021Benefit was seen with daratumumab maintenance therapy for patients with newly diagnosed multiple myeloma who received autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone.
Read More
Promising Responses Seen With Intensified Daratumumab Induction in Ultra High–Risk Multiple Myeloma
June 19th 2021Intensified induction therapy with daratumumab plus cyclophosphamide, bortezomib, lenalidomide, and dexamethasone followed by bortezomib-augmented autologous stem cell transplant resulting in deep remissions or patients with ultra¬ high-risk multiple myeloma or primary plasma cell leukemia.
Read More
CAR T-Cell Therapy Prophylaxis With Anakinra May Reduce CRS and Toxicities in Multiple Myeloma
June 17th 2021The frequency of moderate to severe cytokine release syndrome was reduced in patients with relapsed or refractory multiple myeloma who received anakinra prophylaxis with orvacabtagene autoleucel, a BCMA-targeted CAR T-cell therapy, according to findings presented at the European Hematology Association 2021 Virtual Congress.
Read More
Responses to Zanubrutinib Monotherapy Continue and Deepen in CLL, Updated Results Show
June 16th 2021With longer follow-up, significant responses were still observed with the BTK inhibitor zanubrutinib as a single agent in patients with relapsed or refractory chronic lymphocytic leukemia in the phase 2 BGB-3111-205 trial.
Read More
Cilta-Cel Shows High Response Rate Even After Longer Follow-Up in R/R Multiple Myeloma
June 16th 2021Updated results from the phase 1/2 CARTITUDE-1 trial showed that responses to ciltacabtagene autoleucel were deep and durable in patients with relapsed or refractory multiple myeloma. Data at a median follow-up of 18 months were presented at the 2021 European Hematology Association Congress.
Read More
Lenalidomide Added to Rituximab Following Resistance Leads to Progression Delay in Lymphomas
June 16th 2021Following rituximab resistance, the combination of lenalidomide and rituximab led to durable improvements in outcome for patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas, even after 10 years of follow-up, according to long-term results presented at the European Hematology Association 2021 Congress.
Read More
Phase 3 Front-MIND Trial Initiated to Explore Tafasitamab Triplet in DLBCL
June 16th 2021A phase 3 trial has been initiated to explore the potential of a triplet regimen of tafasitamab-cxix, lenalidomide, and R-CHOP as a treatment options for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Frontline Venetoclax and Obinutuzumab Maintains Delay of Progression in CLL
June 15th 2021With further follow-up from the phase 3 CLL14 trial, the median progression-free survival was still reached with the fixed-dose regimen of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.
Read More
Phlebotomy Requirements Diminished With Rusfertide for Polycythemia Vera
June 15th 2021The hepcidin mimetic rusfertide is suggested to reduce the need for phlebotomy in patients with polycythemia vera, according to the results of the phase 2 PTG-300-04 trial presented during the European Hematology Association 2021 Virtual Congress.
Read More
Without requiring red blood cell transfusions, luspatercept-aamt led to a mean increase in hemoglobin from baseline levels in 77.1% of patients compared with in 0% treated with placebo in patients with non-transfusion–dependent β-thalassemia in the phase 2 BEYOND trial, according to a presentation during the European Hematology Association 2021 Virtual Congress.
Read More
Management Strategy Helps to Mitigate Neurotoxicity Concerns With Cilta-Cel in Multiple Myeloma
June 15th 2021The frequency of neurologic toxicities from ciltacabtagene autoleucel can be reduced with management strategies for patients with relapsed or refractory multiple myeloma treated with the chimeric antigen receptor T-cell therapy, findings from CARTITUDE-2 show.
Read More
Responses Achieved With Zandelisib/Zanubrutinib in R/R CLL, B-Cell Lymphomas
June 14th 2021A combination of zandelisib and zanubrutinib induced significant responses, including several complete responses in patients with relapsed or refractory chronic lymphocytic leukemia and other B-cell lymphomas in a phase 1b study, the results of which were presented during the 2021 European Hematology Association Annual Congress.
Read More
Rituximab Maintenance Improves Time-to-Next Treatment and OS in Patients With Mantle Cell Lymphoma
June 14th 2021Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma, according to a retrospective analysis presented at the European Hematology Association 2021 Virtual conference.
Read More
Cardiovascular Risk Management Requires Further Improvement for MPNs
June 14th 2021A proportion of patients with myeloproliferative neoplasms were not prescribed medications needed for the management of comorbidities in the United Kingdom, a poster presented during the 2021 European Hematology Association Virtual Congress showed.
Read More
Axi-Cel Outperforms Alternate Treatments in R/R Follicular Lymphoma
June 14th 2021Axicabtagene ciloleucel improved outcomes for patients with relapsed/refractory follicular lymphoma over currently available therapies, according to data from a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials.
Read More
Real World Data Show Patients with DLBCL Receive Axi-Cel/Tisa-Cel Prior to Treatment Failure
June 13th 2021Real world data looking at the use of the recently approved CAR T-cell therapies tisagenlecleucel and axicabtagene ciloleucel show that patients are receiving it prior to failing treatments and that 1 in 6 patients were experiencing relapse after treatment.
Read More
Cilta-Cel Significantly Improves Responses for Triple-Class Exposed Myeloma Patients
June 13th 2021Patients with triple-class exposed relapsed or refractory multiple myeloma demonstrated greater efficacy in terms of response and survival from treatment with ciltacabtagene autoleucel in comparison with the standard of care (SOC) in the CARTITUDE-1 trial, according to findings presented at the 2021 EHA Congress.
Read More
Fixed-Duration Ibrutinib/Venetoclax Shows Greater PFS in CLL
June 12th 2021A fixed duration of ibrutinib plus venetoclax led to a significant progression-free survival benefit over chlorambucil plus obinutuzumab as frontline treatment in patients with chronic lymphocytic leukemia, according to a primary analysis of the phase 3 GLOW study presented at the European Hematology Association 2021 Virtual Congress.
Read More
Daratumumab added to the standard of care with lenalidomide and dexamethasone continued to show a survival benefit over Rd alone in patients with transplant-ineligible, newly diagnosed multiple myeloma after almost 5 years of follow-up, updated results from the phase 3 MAIA trial show.
Read More
Naratuximab Emtansine With Rituximab Leads to Durable Responses in R/R DLBCL
June 12th 2021Naratuximab emtansine in combination with rituximab showed deep responses and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma, according to findings from a phase 2 trial presented during the EHA 2021 Virtual Congress.
Read More
Cilta-Cel Outperforms Conventional Therapies in R/R Multiple Myeloma
June 11th 2021Outcomes for patients with relapsed or refractory multiple myeloma who had previously received a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody improved with the use of ciltacabtagene autoleucel as compared with conventional therapies, according to findings from propensity score–matched analyses of the CARTITUDE-1 and MAMMOTH studies.
Read More
Updated Results Show Encouraging Early Signs for Regorafenib Plus Pembrolizumab in advanced HCC
June 10th 2021An updated analysis, presented at the 2021 ASCO Annual Meeting, showed encouraging signs for the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Read More
Belzutifan Shows Strong Responses in RCC and Other VHL-Associated Lesions
June 9th 2021Updated findings for belzutifan showed that with further follow-up, the hypoxia-inducible factor-2 alpha inhibitor continues to show significant clinical activity in patients with Von-Hippel Lindau–associated renal cell carcinoma treated in the frontline setting. Updated results from the phase 2 study.
Read More
Pembrolizumab Plus Cabozantinib Achieves High Response Rate in Metastatic RCC
June 9th 2021More the half of patients with metastatic renal cell carcinoma who received pembrolizumab in combination with cabozantinib had a response to the combination at the recommended phase 2 dose and tolerated treatment well.
Read More
Efficacy Improved with Lenvatinib/Pembrolizumab Combo Over Sunitinib Across RCC Risk Groups
June 9th 2021Efficacy was improved with Lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups over sunitinib.
Read More
Second-line treatment with cetuximab in patients with metastatic colorectal cancer given after irinotecan or oxaliplatin-based regimen failure, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.
Read More